The global spatial genomics & transcriptomics market size was estimated at USD 149.4 million in 2018. Spatial genomics & transcriptomics is a relatively new discipline that involves the determination of high-throughput data pertaining to the organizational structure of cell content from tissue and cell specimens. Conventional genomic techniques lose positional information of the nucleic acid content, which has been addressed by the advent of this technology. Moreover, rapid advancements in the genomics arena, ranging from tissue sequencing to single-cell sequencing, have significantly benefitted spatial genomic sequencing techniques. This is because single cell sequencing enables the identification of the spatial origin of cells to characterize complex tissues.
Spatial patterns of the genome have been identified for several medical conditions, which has resulted in the implementation of spatial information as a diagnostic biomarker for various diseases. Growing demand for biomarkers, which enable differentiation of benign tumor from the malignant tumor with higher accuracy, boosts the demand for spatial genomic analysis as a cancer diagnostic tool.
The high adoption rate of in situ sequencing techniques for identification of the spatial distribution of reads in a sample drives the market. Market participants are undertaking efforts to address the increasing demand for advanced sequencing techniquesto study architectural patterns.
For instance, in February 2018, Dovetail LLC launched Dovetail Hi-C and Fix-C with Selva structural variation detection software. This is the first commercial service for the study 3-D structure genome structure of diseased specimens. Moreover, an increase in funding initiatives for genomic and transcriptomic studies has created significant opportunities for companies to expand their businesses.
For instance, in January 2018, ReadCoor received a grant from the Silicon Valley Community Foundation (DAF) and Chan Zuckerberg Initiative for spatial mapping of cortical cells. Similarly, in April 2017, Seven Bridges invested in the Spatial Transcriptomics AB for the development of a set of tools for the visualization of gene expression within tissue samples for biomedical analysis.
The substantial applicability of spatial transcriptomic sequencing methods for the transcriptomic study of single cells, as compared to spatial genomic methods, has resulted in the larger revenue share of this method. The dominance of this segment is also attributive to the adoption of automated sequencing workflows such aslaser capture microdissection technique (LCM) to address the rising demand for nucleic acid sequencing of single cells or biological specimens.
The LCM technique facilitates effective isolation of small tissue regions or cells from defined anatomical locations without losing the spatial information. Availability of an extensive range of genome-wide nucleic acid amplification methods that can be used for amplification of LCM-extracted RNA, is attributive for the estimated share of this segment in thespatial genomics & transcriptomics market.
Realizing the significance of this market in future disease management, key players are striving to capitalize on untapped lucrative avenues of the market. The entities are undertaking various business strategies to expand their footprint in the market. For instance, in December 2018, 10x Genomics entered this market through the acquisition of Stockholm-based company, Spatial Transcriptomics.
Revenue flow from the consumables segment was estimated to be highest in 2018. Attributing factors include wide availability of reagents and kits, increased usage rate, and frequent purchase of consumables, which results in higher penetration of consumables to run the instruments. Numerous genetics-related research studies are integrating robust software solutions for data management and interpretation. The introduction and employment of automated data analysis software by companies is anticipated to result in the lucrative growth of software.
The translational research segment accounted for the dominant revenue share in 2018 and is anticipated to continue this trend throughout the forecast period. This can be attributed to the wide application of spatial genomics techniques in translational studies to analyze the behavior of human tissues and cells from other individuals.
In addition, several research organizations have introduced study programs, such as BRAIN Initiative launched by NIH, to leverage the application of spatial transcriptomic in the field of disease diagnosis. Furthermore, neuroscientists have started the implementation of single-cell transcriptomics research in order to understand the architecture of nervous tissues.
Academic customers are expected to emerge as a lucrative source of revenue during the forecast period owing to the increase in sequencing-based research programs in universities. Furthermore, continuous funding programs to accelerate research projects in universities drives the segment progression.
North America dominated the market by revenue due to increasing adoption of solutions for spatial profiling in cancer research, coupled with rising focus on genomics-based R&D. For instance, the GeoMx platform by U.S.-based NanoString Technologies, Inc. has been implemented in more than 70 research projects, focusing on approximately 25 cancer types.
Asia Pacific is anticipated to register the highest CAGR due to rising investments by public and private agencies. For instance, in 2018, research involving prediction of gene regulatory networks from transcriptome datasets was jointly funded by Grant-in-Aid for Scientific Research from Japan Society for the Promotion of Science, Advanced Low Carbon Technology Research and Development Program (ALCA), and CREST by Japan Science and Technology Agency.
Some of the key participants operating in this market are 10x Genomics; Dovetail Genomics; Illumina, Inc.;S2 Genomics, Inc.; NanoString Technologies; Seven Bridges Genomic; Horizon Discovery Group plc; CARTANA AB; and Advanced Cell Diagnostics.
Mature players are involved in the development of novel platforms to maintain their market position. Funding from government bodies assist emerging players in broadening their product offerings. For instance, in June 2018, S2 Genomics received Phase I STTR grant from the National Institute of Health for the development of a singulator system for automated preparation of single nuclei.
Base year for estimation
Actual estimates/Historical data
2014 - 2017
2019 - 2025
North America, Europe, Asia Pacific, Latin America, & MEA
Revenue in USD Thousand & CAGR from 2019 to 2025
U.S., Canada, Germany, U.K., Japan, China, Brazil, South Africa
Revenue forecast, company share, competitive landscape, growth factors and trends
15% free customization scope (equivalent to 5 analyst working days)
If you are looking for specific or additional information, which is not currently within the scope of the report, we will provide it to you as a part of customization
This report forecasts revenue growth at global, regional, and country level and provides an analysis on latest industry trends and opportunities in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the global spatial genomics & transcriptomics market report on the basis of technology, product, end use, and region:
Technology Outlook (Revenue, USD Thousand, 2014 - 2025)
Laser Capture Microdissection (LCM)
FFPE Tissue Samples
Transcriptome In-Vivo Analysis (TIVA)
In Situ Sequencing
Microscopy-based RNA Imaging Techniques
Single Molecule RNA Fluorescence In-Situ Hybridization (smFISH)
Padlock Probes/ Rolling Circle Amplification
Branched DNA Probes
Microscopy-based Live DNA Imaging
Genome Perturbation Tools
Product Outlook (Revenue, USD Thousand, 2014 - 2025)
Storage and Management Databases
End-use Type Outlook (Revenue, USD Thousand, 2014 - 2025)
Regional Outlook (Revenue, USD Thousand, 2014 - 2025)
Middle East and Africa (MEA)
b. The global spatial genomics and transcriptomics market size was estimated at USD 48.6 million in 2019 and is expected to reach USD 52.8 million in 2020.
b. The global spatial genomics and transcriptomics market is expected to grow at a compound annual growth rate of 7.8% from 2020 to 2025 to reach USD 76.2 million by 2025
b. Spatial transcriptomics dominated the spatial genomics and transcriptomics market with a share of 79% in 2019 owing to wide scale implementation of spatial transcriptomic sequencing methods for the transcriptomic profiling of single cells
b. Some key players operating in the spatial genomics and transcriptomics market include 10x Genomics; Dovetail Genomics; Illumina, Inc.;S2 Genomics, Inc.; NanoString Technologies; Seven Bridges Genomic; Horizon Discovery Group plc; CARTANA AB; and Advanced Cell Diagnostics.
b. Key factors that are driving the market growth include emergence of fourth generation of sequencing and increasing demand for robust and early diagnostics in cancer management
Avail customized purchase options to meet your exact research needs:
Get your queries resolved from an industry expert.
Design an exclusive study to serve your research needs.
A testimonial for service in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.
"The quality of research they have done for us has been excellent..."
Biopharmaceutical innovators are at the forefront of the human response to the coronavirus pandemic. A significant number of major biotech firms are in the midst of a race to investigate the Sars-Cov-2 genome and prepare a viable vaccine for the same. As compared to the speed of response to SARS/MERs etc, the biotech entities are investigating SARs-Cov-2 at an unprecedented rate and a considerable amount of funds are being put into the R&D. With multiple candidates in trial, the public and private sectors are anticipated to work in unison for the foreseeable period, until a vaccine is developed for Covid-19. The report will account for Covid19 as a key market contributor.